PROGNOSTIC GROUPING OF OVARIAN CANCER PATIENTS

摘要

The present invention relates to molecular profiling in order to identify clinically applicable biomarkers for stratifying cancer patients having different responses to a certain therapy. Specifically, the present invention provides clinically applicable methods and means for predicting the response to the platinum and taxane combination therapy in cancer patients, especially in high-grade serous ovarian cancer (HGS-OvCa) and basal like breast cancer (BL-BrCa) patients. The method of the invention comprises determining the set of biomarkers in patient samples obtained from patients suffering from HGS-OvCa; and determining outcome groups for cancer patients based on the expression of the set of biomarkers. A panel of biomarkers and a kit is also provided. The invention provides substantial help in the clinical decision making and is especially useful in the selection of first line chemotherapy regimen.